EnhanX Biopharma

EnhanX Biopharma is a biotechnology company focused on developing next-generation cytokine-based immunotherapies for cancer and autoimmune diseases. The company's core technology centers on a proprietary masking platform that creates conditionally active biologics, designed to minimize systemic side effects while maximizing therapeutic activity within the tumor microenvironment. Its lead candidate, ENX-101, is a masked Interleukin-2 (IL-2) prodrug currently in Phase 1 clinical trials for the treatment of advanced solid tumors. By engineering cytokines with improved safety profiles, EnhanX aims to unlock the full potential of immune-modulating proteins that have historically been limited by toxicity. The company maintains a dual presence in Shanghai and Cambridge, leveraging global expertise in drug discovery and clinical development.